- New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve
- Next-generation therapy offers enhanced leaflet grasping feature and new clip sizes to fit each patient’s complex tricuspid valve anatomy
- TriClip G4 makes treatment more customizable, expanding options for physicians seeking innovative transcatheter structural heart solutions
Abbott announced it has received CE Mark for its next-generation TriClip™ Transcatheter Tricuspid Valve Repair System, the first-of-its-kind minimally invasive tricuspid heart valve repair device available in Europe to treat tricuspid regurgitation (TR). The clip-based therapy, known as TriClip G4, is a non-surgical heart valve repair option specifically designed for the treatment of TR, or a leaky tricuspid valve, that allows physicians to tailor repair of the valve to each patient’s unique anatomy.
“Since its initial CE Mark in April 2020, TriClip has emerged as a much-needed treatment option, offering physicians the opportunity to dramatically improve the quality of life for people in Europe with severe, symptomatic tricuspid regurgitation who are not responding to medical therapy and are often so ill they cannot undergo surgery,” said Philipp Lurz, M.D., Ph.D., professor and deputy head of cardiology, Heart Center Leipzig, University of Leipzig, Leipzig, Germany. “This newest generation device further improves cardiologists’ ability to safely and effectively repair the tricuspid valve, which historically has been extremely challenging to treat.”